In addition, this study may bring new insights in the field of hemostasis inhibitor-based treatment in severe sepsis: indeed, although the efficiency of coagulation inhibitors is still controversial [59], downregulation of VWF-mediated thrombosis by exogenous ADAMTS13 brought by plasma infusions, or in the future by plasma-purified or recombinant ADAMTS13, may be an interesting new approach targeted on primary hemostasis. Here, ADAMTS13 is linked to Sepsis.